Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Teva Pharm tops quarterly estimates
Teva on track for worst intraday loss in years on guidance miss
Teva Pharmaceutical (TEVA) stock falls as the generic drugmaker with its Q4 2024 results set its 2025 earnings outlook below consensus. Read more here.
Teva Pharm tops quarterly estimates but 2025 earnings outlook falls short
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia.
Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript
Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call. My name is Alex, and I will be coordinating the call today. [Operator instructions] And I hand it over to your host,
23h
Why Teva Pharmaceutical Stock Is Sinking Today
Shares of Teva Pharmaceutical Industries ( TEVA -13.66%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p ...
6h
on MSN
Why Teva Pharmaceuticals (TEVA) Crashed on Wednesday?
We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...
1d
on MSN
Teva Pharma CEO: Guidance based on the new Teva that grows every year
Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, drug ...
7h
Teva price target lowered to $27 at UBS, says pullback ‘somewhat unfair’
UBS lowered the firm’s price target on Teva (TEVA) to $27 from $30 and keeps a Buy rating on the shares. UBS says the pullback on the stock ...
FiercePharma
1d
Teva, despite delivering in 2024, startles investors with subdued 2025 guidance
Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...
7h
What Analysts Are Saying About Teva Pharmaceutical Indus Stock
Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...
7h
Teva price target lowered to $26 from $28 at Barclays
Barclays lowered the firm’s price target on Teva (TEVA) to $26 from $28 and keeps an Overweight rating on the shares. The post-earnings selloff ...
5d
Teva (yes, like the sandals) makes winter boots now. We tested them in a polar vortex.
Teva’s first pair of true winter boots deliver on their promises. They’re not meant for arctic adventures but are great at ...
Hosted on MSN
1d
Teva Stock Dives 14%. Why Its CEO Says It's A Victim.
Teva Pharmaceutical is a victim of its own success, Chief Executive Richard Francis said Wednesday as Teva stock plummeted on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
United States
Q4
Trade
Food and Drug Administration
Golimumab
Feedback